Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 13

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 13
---
 product candidates or such quantities at an acceptable cost or 
 quality, which could delay, prevent or impair our development or commercialization efforts.                                                                                                                                                          |

| • |     | If we or our licensors are unable to obtain, maintain and enforce intellectual property rights relating to any of our                                                                                                                                 
 product candidates, or if the scope of the protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize our 
 product candidates may be adversely affected and we may not be able to compete effectively in our markets.                                                                                                                                            |

| • |     | We face substantial competition. Our main competitor in the CF market holds substantial market share and has substantially                         
 greater resources than we do. We may not be able to compete successfully in this environment and, in particular, against a much larger competitor. |

9

| • |     | There has been no prior public market for our common stock. An active trading market for our common stock may not develop 
 or be sustained.                                                                                                          |

| • |     | The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could lose all or 
 part of their investment.                                                                                                 |

The summary risk factors described above should be read together with the text of the full risk factors in the section titled “ Risk Factors” and the other information set forth in this prospectus, including our audited consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission (the “SEC”). The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects. Corporate Information We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA 02451, and our telephone number is (617) 819-2020.We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts. Our website address is www.sionnat